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Abstract 
Changes in stride characteristics and gait rhythmicity characterise gait in Parkinson’s disease 
and are widely believed to contribute to falls in this population.  However, few studies have 
examined gait in PD patients who fall.  This study reports on the complexities of walking in 
PD patients who reported falling during a 12 month follow-up.  Forty-nine patients clinically-
diagnosed with idiopathic PD and 34 controls had their gait assessed using three-dimensional 
motion analysis.  Of the PD patients, 32 (65%) reported at least one fall during the follow-up 
compared with 17 (50%) controls.  The results showed that PD patients had increased stride 
timing variability, reduced arm swing and walked with a more stooped posture than controls. 
Additionally, PD fallers took shorter strides, walked slower, spent more time in double-
support, had poorer gait stability ratios and did not project their centre of mass as far forward 
of their base of support when compared with controls.  These stride changes were 
accompanied by a reduced range of angular motion for the hip and knee joints.  Relative to 
walking velocity, PD fallers had increased mediolateral head motion compared with PD non-
fallers and controls.  Therefore, head motion could exceed ‘normal’ limits, if patients 
increased their walking speed to match healthy individuals.  This could be a limiting factor 
for improving gait in PD and emphasises the importance of clinically assessing gait to 
facilitate the early identification of PD patients with a higher risk of falling. 
 
Keywords:   Falls; Motion Analysis; Kinematics; Gait; Postural Control  
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Introduction 
Parkinson’s disease (PD) is an age-related neurodegenerative condition characterised by 
slowness of movement (bradykinesia)1, muscle rigidity (akinesia)1-3 and resting tremor2, 4, but 
as the disease progresses postural instability1, 5 and gait difficulties1, 4 begin to affect activities 
of daily living.  Declines in physical functioning effectively expose people with PD to a nine 
times greater risk of recurrent falls6, and a five times greater risk of sustaining fall-related 
injuries7 compared with healthy individuals of a similar age.  A recent meta-analysis of six 
prospective studies showed that approximately 46% of the PD patients reported at least one 
fall in the 3-month follow-up period8.  Cross-sectional studies indicate that difficulties with 
gait and dynamic postural control play an important role in many of these falls, of which 
nearly half occur during walking, turning or other forms of ambulation9.  
 
While there have been numerous studies documenting changes in the gait characteristics of 
PD patients with respect to healthy age-matched controls, only three have examined the gait 
patterns of PD patients who fall.  In an earlier study, Schaafsma et al.10 reported that stride 
timing variability was significantly greater in PD patients who had a history of falling while 
both on and off medication.  More recently, a cross-sectional study by Latt et al.11 showed 
that PD fallers walked more slowly than PD non-fallers and controls, took shorter steps than 
controls, but maintained the same stride frequency (cadence).  Furthermore, PD fallers had 
lower harmonic ratios for pelvic and head movement in both the anteroposterior and vertical 
directions (less rhythmic), implying reduced walking stability in this sub-population11.  In 
contrast, the subsequent prospective study of these patients by Latt et al.12 reported that step 
length, walking speed and step timing variability was not significantly different for PD fallers 
compared with non-fallers, but cadence was significantly decreased.  While this prospective 
study employed the gold-standard methods for recording falls13, the analysis of the gait-
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related data was limited to the temporospatial characteristics and did not include more 
complex parameters that are likely to contribute to balance control and falls.  Therefore, this 
research aimed to examine the three-dimensional gait characteristics of PD patients who 
prospectively reported falling over a twelve month period, with the intent of identifying 
kinematic quantities that might characterise fallers and be amenable for modification through 
tailored interventions.  It was hypothesised that PD fallers would show differences in 
temporospatial and joint kinematic quantities compared with non-fallers and controls and 
would have poorer control of the head and pelvis during walking. 
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Methodology 
Study Population 
Forty-nine participants who were clinically diagnosed with idiopathic PD (66.4 ± 1.2 yrs) 
were recruited from community support groups and neurology clinics in South-East 
Queensland between March 2005 and December 2006.  During the same period, thirty-four 
healthy controls (67.6 ± 1.6 yrs) were randomly recruited from the Brisbane metropolitan 
area via the Australian electoral role.  Participants were sent a letter of invitation and an 
information sheet, which outlined the potential risks and benefits of the research and were 
then contacted by telephone to establish their interest in participating.  Participants were 
excluded if they had a recent or recurrent history of musculoskeletal injury or surgery, were 
unable to ambulate independently without the use of a walking aid, or had any significant 
visual (Bailey-Lovie high contrast visual acuity >0.30 logMAR) or cognitive impairment 
(Mini Mental State Exam14 score <24 out of 30).  Participants gave written informed consent 
to participate in accordance with the Declaration of Helsinki and the experimental protocol 
was approved by the Human Research Ethics Committee at the Queensland University of 
Technology.  Based on previous studies of walking and postural stability in PD15, 16, it was 
considered that a minimum of 15 people per group would be sufficient to detect differences 
between groups. 
 
Insert Table 1 about here. 
 
Clinical Assessment 
During an initial session scheduled up to one week prior to the gait assessment, an 
experienced movement disorders specialist established patients’ disease severity using 
standard clinical tests, including the Unified Parkinson’s Disease Rating Scale17 (UPDRS) 
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and the Hoehn & Yahr (H&Y) score18.  Fear of falling and freezing of gait were assessed 
using the Modified Falls Efficacy Scale19 and the Freezing of Gait (FOG)20 questionnaire, 
respectively.  A measure of postural instability and gait disability (PIGD) was derived by 
summing the scores for items 13 to 15 and 27 to 30 from the UPDRS.  All but five PD 
patients (10.0%) were treated with levodopa or dopamine agonist supplementation and all 
procedures were undertaken within 1 to 2 hours of a medication dose to ensure that the 
patients were optimally-medicated at the time of testing. 
 
Three-Dimensional Gait Assessment 
Participants performed six trials consisting of walking barefooted at a self-selected pace 
along a firm walkway (L: 12 m x W: 2.2 m x H: 0.1 m).  Twenty-eight spherical markers 
were positioned on the body in accordance with the Helen Hayes marker set21, which was 
modified to include the upper body and head.  Markers were attached over specific 
anatomical landmarks on the trunk (sacrum, sternum, C7 spinous process), arms (lateral 
border of the acromion, olecranon process of the humerus, radial and ulnar styloids), and 
head (supra-auricular point, top of the head).  Markers were attached over bony landmarks by 
the same experienced movement specialist to minimise errors associated with skin movement 
and marker placement. 
 
Marker positions were tracked within the central 4 m length of the 12 m walkway (50 Hz) by 
a previously calibrated six-camera motion analysis system (Motus 2000; Vicon, Oxford, UK) 
for two complete gait cycles (1 right; 1 left).  The data were reconstructed using the direct 
linear transformation (DLT) algorithm22 and the full body linked-segment model was used to 
calculate temporospatial gait parameters and angular quantities for the lower limbs.  These 
included stride length, step width, cadence, double support (percent of gait cycle with both 
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feet on the ground), walking velocity (stride length/stride period), stride timing variability 
(SD of stride period)23 and the Gait Stability Ratio (stride frequency/walking velocity)24.    
The position of the centre of mass (COM) relative to the base of support (BOS) was 
examined in the mediolateral (ML) and anteroposterior (AP) directions and the ML and 
vertical (VT) displacement of the head and pelvis were assessed to provide a measure of 
segmental control.  Arm swing was calculated as displacement of the wrists in the sagittal 
plane.  These variables were selected because it was believed that older individuals seek to 
reduce stride length and walking velocity and increase double support time to better control 
the body and minimise postural instability25.  Similar compensatory changes in 
temporospatial gait characteristics have been shown for PD patients15, 26, 27, but it is unclear 
whether these changes improve postural stability in this population. 
 
Angular kinematics of the trunk, hip, knee and ankle joints were also examined in the sagittal 
plane.  Trunk flexion angle was defined as the angle formed between the vector joining the 
markers positioned on the sacrum and C7 spinous process and the vertical axis of the global 
coordinate system.  Hip flexion/extension angle was calculated as the angle formed between 
the vertical axis of the pelvis segment and the vector joining the hip and knee joints in the 
sagittal plane.  Similarly, knee flexion/extension was measured as the motion between the 
vectors joining the hip and knee joints and the knee and ankle joints.  Ankle plantar- and 
dorsi-flexion was calculated as the angle formed between the vector joining the ankle joint 
and the second metatarsal joint, where zero degrees was the point at which the two vectors 
were perpendicular to each other. 
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12-Month Prospective Follow-up. 
Following testing, the participants were asked to record any falls or injuries that they 
experienced on a daily falls calendar, which they returned on a monthly basis via a reply-paid 
envelope over the subsequent 12-month period.  When participants reported having a fall, 
they were asked to provide additional information related to the timing, location and cause of 
the fall.  If participants failed to complete their monthly calendars they were sent reminders 
by mail and received follow-up phone calls.  For the purposes of this study, a fall was defined 
as “an unintentional coming to the ground or some lower level not as a result of a major 
intrinsic event (e.g. stroke or syncope) or overwhelming hazard”28. 
 
Statistical Analysis. 
Analysis of variance (ANOVA) was used to determine mean differences between PD patients 
and controls and the four faller groups for the demographic, temporospatial and joint 
kinematic variables.  To determine where statistically significant differences existed between 
faller and non-faller groups, the Tukey’s Honestly Significant Difference (HSD) post-hoc test 
was used.  The HSD procedure controls for the overall significance level when performing all 
pairwise comparisons in ANOVA and therefore reduces the likelihood of a Type 1 error.  In 
circumstances where the assumptions of the ANOVA were violated, the non-parametric 
Kruskal-Wallis Test was used.  The degree of association between the categorical variables 
was assessed with the chi-square (χ2) test.  All statistical procedures were conducted using 
SPSS 16 and the level of significance was set at p < 0.05.
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Results 
Falls 
During the 12-month follow-up, 32 (65%) PD patients and 17 (50%) control participants 
reported at least one fall, while 21 (43%) PD and 9 (27%) control participants reported falling 
twice or more.  Based on the prospective falls data, participants were divided into four 
groups; PD Fallers (n = 32); PD Non-Fallers (n = 17); Control Fallers (n = 17); and Control 
Non-Fallers (n = 17). 
 
Clinical Characteristics 
PD and control participants were of similar age, height, mass and BMI, and had similar 
scores for the MMSE and Bailey-Lovie high contrast visual acuity.  The modified falls 
efficacy scale showed that PD fallers had an increased fear of falling compared to PD non-
fallers and controls and reported more falls during the previous 12 months than PD and 
control non-fallers.  PD fallers and non-fallers had similar disease severity based on the 
UPDRS, H&Y and PIGD score, but PD fallers had a significantly greater disease duration 
and FOG score than non-fallers.  Average daily Levodopa dose was not different between the 
PD fallers and non-fallers (Table 1). 
 
Temporospatial Characteristics 
 
Insert Figure 1 about here. 
 
PD fallers walked significantly more slowly than PD non-fallers and control participants and 
took significantly shorter strides than controls (Figure 1).  PD fallers had higher (poorer) gait 
stability ratios and spent significantly more time in the stance phase and double support when 
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compared to controls.  Despite these findings, PD non-fallers did not differ significantly from 
controls for any of the temporospatial measures. 
 
Segmental Motion 
 
Insert Figure 2 about here. 
 
PD fallers had significantly reduced arm swing and did not project their COM as far forward 
of their BOS compared to the control participants (Figure 2).  However, further analysis of 
the data showed that the position of the COM relative to the BOS was directly proportional to 
walking speed.  The groups did not differ for mediolateral head and pelvis motion (Table 2), 
but normalisation of these data to walking speed demonstrated that PD fallers had 
significantly increased mediolateral head motion compared with PD non-fallers and controls 
(Figure 3).  Furthermore, there was a tendency for PD fallers to have increased mediolateral 
pelvis motion compared with PD non-fallers and controls, but this did not achieve statistical 
significance.  Normalised mediolateral head motion and arm swing were negatively 
correlated for the whole sample (Spearman’s ρ = -0.383; p < 0.001), indicating that increased 
arm swing corresponded with reduced mediolateral head motion. 
 
Insert Figure 3 about here. 
 
Joint Kinematics 
PD fallers had a reduced range of knee flexion/extension compared to PD non-fallers and 
controls and had reduced hip flexion/extension compared with the controls.  However, there 
were no differences between the groups for trunk flexion or ankle plantar- and dorsi-flexion 
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(Table 2).  PD non-fallers did not differ significantly from controls for any of the angular 
measures and normalisation of the joint ranges to stride length yielded similar angular ranges 
for all four groups. 
 
Insert Table 2 about here. 
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Discussion 
This study is one of the first to fully categorise segmental control during walking in 
Parkinson’s disease patients who reported falling in the ensuing 12 months.  The findings 
demonstrated that PD fallers have very different walking patterns to healthy controls (either 
fallers or non-fallers) and identified a trend of declining gait performance from the control 
non-fallers to the PD fallers.  The temporospatial findings were in agreement with those 
presented previously for PD patients with respect to healthy controls15, 16, 26, 27, 29, 30 and one 
cross-sectional study that compared PD fallers, non-fallers and controls11.  However, they 
were in contrast to those of a recent prospective study, which reported reduced cadence, but 
no differences in step length or walking velocity for PD fallers compared with PD non-
fallers12. 
 
The joint kinematics confirmed previous reports of a more stooped walking posture31, 32 and 
reduced lower limb joint mobility15, 30 in PD patients.  However, expressed relative to stride 
length, these joint angle differences were negated and were commensurate with the slower 
walking velocity of PD fallers.  Therefore, it was unclear whether the differences observed 
for the PD fallers were related to reduced joint mobility or the adoption of a more “cautious” 
gait pattern.  Shorter stride length and slower walking velocity have been suggested to result 
from muscle weakness or postural abnormalities in PD5, 33 and older adults may adopt these 
characteristics in an attempt to improve stability by reducing upper body motion34.  Such 
stride changes in PD patients are thought to arise from deficits in basal ganglia output to the 
supplementary motor area and pre-motor cortex15, 35, which lead to a mismatch between the 
selected and actual size of well-learned and repetitive movement sequences15, 35.  
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Reduced arm swing was observed in the PD groups and has been reported extensively in the 
previous literature e.g. 36-38 as one of the first presenting features of PD37, 39.  Unlike lower limb 
kinematics, this characteristic was not accounted for by differences in walking speed, which 
suggests it was independent of the other changes.  Recent evidence shows that the arms 
contribute to walking efficiency, by reducing vertical ground reaction moments40 and/or 
improving lateral stability41.  This notion was supported by the finding that, relative to 
walking speed, PD fallers had significantly increased mediolateral head motion.  The 
negative bivariate relationship between normalised mediolateral head motion and arm swing 
is consistent with such a mechanism.  Conversely, Latt et al.11 reported no significant 
differences between PD fallers and non-fallers for mediolateral stability of the head or pelvis, 
following adjustment for velocity and step timing variability, but reported significantly 
improved stability in controls.  These authors theorised that PD patients might walk with an 
increased step width to maintain mediolateral stability11; however our data did not support 
this.  Our findings, instead, suggest that if patients were to increase their walking speed, 
mediolateral head motion would likely exceed ‘normal’ limits.  Consequently, their shorter 
stride lengths may be driven by the need to maintain control of the upper body, which 
comprises approximately 60 to 70 percent of the body’s mass42.  This notion is supported by 
the observation that older adults who walked more slowly exhibited improved local and 
orbital stability43 and that mediolateral head stability is optimised (higher harmonic ratio) at 
slower walking velocities in younger participants44. 
 
It is worth noting, that the PD fallers had an increased fear of falling, which has previously 
been associated with declines in gait performance45.  While this fear may have emanated 
from the greater number of previous falls experienced by these patients, it could also reflect a 
greater awareness of deficits in walking stability. 
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A possible limitation of this research is that the PD participants were predominantly early 
stage patients (H&Y ≤ 2).  Nonetheless, the results demonstrated that falls are a significant 
problem even in the early stages of PD and that the observed impairments in postural control 
could be exacerbated in later stage PD patients who are known to have an increased risk of 
falling. 
 
This study demonstrates the complexity of gait problems in PD patients who fall.  It is 
suggested that, while it may be possible to improve the efficiency and appearance of gait in 
PD patients with the use of visuale.g. 15, 46 or auditory cuese.g. 47, 48, these improvements may 
exacerbate mediolateral instability of the head and inherently increase the risk of falling.  
Therefore, it is important to ensure that these gait characteristics are assessed clinically to 
facilitate the early identification of PD patients who have a higher propensity to falling.  
Furthermore, knowledge of such differences in the stride characteristics and segmental 
control provides scientists and clinicians with information that may aid the development of 
more effective intervention strategies to assist in preventing falls in this population. 
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Figure Captions 
Figure 1: Mean (+1 SEM) stride length, walking speed, gait stability ratio and double-support 
time for the PD fallers, PD non-fallers, control fallers and control non-fallers (* p < 0.05). 
 
Figure 2: Average (+1 SEM) arm swing and projection of the centre of mass relative to the 
base of support in both the anteroposterior (AP) and mediolateral (ML) directions 
(* p < 0.05). 
 
Figure 3: Mean (+1 SEM) mediolateral and vertical displacement of the head and pelvis (a) 
unadjusted for walking speed and (b) adjusted for walking speed (* p < 0.05). 
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Table Captions 
Table 1: Demographic details and disease-specific scores for the Parkinson’s disease and 
Control participants and the faller and non-faller sub-groups. 
 
Table 2: Temporospatial characteristics, segmental coordination and sagittal joint kinematics 
for the Parkinson’s disease and Control fallers and non-fallers. Data represent the mean (and 
standard error of the mean (SEM)) values. 
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Tables 
PARKINSON’S DISEASE
 Patients with PD     
(n = 49) 
 Non-Fallers   
(n = 17) 
Fallers          
(n = 32) 
 Test p-value 
Demographics        
Age (years) 66.4 (1.2)  66.9 (2.1) 66.2 (1.4)  1 0.772 
Gender (male) 33 (67.3%)  13 (76.5%) 20 (62.5%)  2 0.321 
Height (cm) 167.1 (1.1)  166.6 (1.7) 167.3 (1.4)  1 0.742 
Weight (kg) 73.8 (1.9)  69.4 (2.8) 76.1 (2.5)  3 0.231 
BMI (kg/m2) 26.4 (0.6)  24.9 (0.8) 27.1 (0.8)  1 0.068 
    
Falls History and Fear of Falls        
Modified Falls Efficacy Scale 8.7 (0.3)  9.7 (0.1) 8.3 (0.4)  3 0.005 
Previous Falls 2.9 (2.0)  0.3 (0.1) 4.3 (3.1)  3 0.013 
        
Visual and Cognitive Functioning        
High Contrast Visual Acuity (LogMAR) 0.00 (0.01)  -0.02 (0.02) 0.01 (0.02)  3 0.259 
Mini-Mental State Exam 27.4 (0.3)  27.8 (0.5) 27.1 (0.4)  1 0.258 
    
Neurological Exam        
Disease Duration (years)  5.4 (0.5)  3.9 (0.6) 6.2 (0.7)  3 0.044 
Levodopa dose (mg/day) 657.6 (75.7)  598.8 (75.8) 688.8 (109.2)  3 0.736 
Freezing of Gait 4.0 (0.6)  2.1 (0.6) 5.0 (0.7)  3 0.004 
Hoehn & Yahr 1.8 (0.1)  1.6 (0.2) 1.8 (0.1)  3 0.393 
UPDRS Total 31.8 (2.3)  26.6 (3.7) 34.5 (2.7)  1 0.097 
PIGD 3.9 (0.5)  3.0 (0.6) 4.4 (0.6)  1 0.156 
CONTROLS 
 All Controls    (n = 34)  
Non-Fallers 
(n = 17) 
Fallers          
(n = 17)  Test p-value 
Demographics        
Age (years) 67.6 (1.6)  65.1 (2.1) 70.2 (2.3)  1 0.109 
Gender (male) 20 (58.8%)  10 (58.8%) 10 (58.8%)  2 1.000 
Height (cm) 168.6 (1.5)  169.8 (2.1) 167.5 (2.0)  1 0.437 
Weight (kg) 77.6 (2.8)  79.1 (3.9) 76.0 (4.0)  3 0.730 
BMI (kg/m2) 27.1 (0.7)  27.3 (0.9) 26.9 (1.1)  1 0.824 
      
Falls History and Fear of Falls        
Modified Falls Efficacy Scale 9.7 (0.1)  9.7 (0.1) 9.7 (0.2)  3 0.926 
Previous Falls 0.4 (0.1)  0.3 (0.2) 0.5 (0.2)  3 0.167 
      
Cognitive Functioning        
High Contrast Visual Acuity (LogMAR) 0.01 (0.01)  0.00 (0.01) 0.02 (0.02)  3 0.357 
Mini-Mental State Exam 27.8 (0.4)  27.8 (0.6) 27.7 (0.6)  1 0.890 
    
N.B. Data are mean (+1 SEM) or absolute numbers and percentages. Test 1 = one-way ANOVA; Test 2 = χ2 test;            
Test 3 = Kruskal-Wallis Test 
Table 1. 
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   PD Faller  PD Non-Faller  Control Faller  Control Non-Faller  
   (n = 32)  (n = 17)  (n = 17)  (n = 17)  
   Mean SEM  Mean SEM  Mean SEM  Mean SEM Sig. 
Temporospatial              
Stride Length (m)  1.10 0.03  1.21 0.04  1.25 0.03  1.30 0.04 a, c, d 
Step Width (cm)  8.41 0.50  8.03 0.65  8.17 0.80  9.23 0.75 ns 
Cadence (steps/s)  1.86 0.04  1.90 0.03  1.95 0.02  1.97 0.05 ns 
Stance Phase (%)  62.64 0.40  61.68 0.27  60.87 0.50  60.46 0.49 a, c, d 
Swing Phase (%)  37.36 0.40  38.32 0.27  39.13 0.50  39.54 0.49 a, c, d 
Double Support (%)  25.54 0.77  23.20 0.55  21.76 1.06  21.12 1.04 a, c, d 
Single Support (%)  74.75 0.79  76.68 0.54  78.29 1.01  79.11 0.99 a, c, d 
Velocity (m/s)  1.03 0.04  1.15 0.04  1.22 0.04  1.28 0.05 a, b, c, d
Stride Timing Variability  29.87 2.27  28.65 2.58  22.39 1.59  24.64 2.04 a 
Gait Stability Ratio  1.87 0.06  1.68 0.05  1.62 0.04  1.57 0.04 a, c, d 
Segmental Motion (cm)              
Avg Arm Swing  21.55 2.33  25.39 2.16  28.54 1.66  34.24 2.64 a, c, d, f 
COM to BOS - AP  27.16 0.94  30.72 0.99  31.30 1.10  32.33 1.35 a, c, d 
COM to BOS - ML  -4.05 0.23  -3.86 0.27  -3.84 0.29  -4.36 0.24 ns 
Head Motion - VT  2.95 0.17  3.22 0.17  3.49 0.20  3.79 0.31 a 
Head Motion - ML  5.34 0.30  4.53 0.26  4.88 0.26  5.22 0.37 ns 
Pelvis Motion - VT  2.95 0.16  3.23 0.17  3.45 0.19  3.71 0.30 a 
Pelvis Motion - ML  4.42 0.25  4.12 0.21  4.44 0.26  4.65 0.19 ns 
Norm Head Motion - VT  2.86 0.12  2.80 0.11  2.85 0.12  2.96 0.18 ns 
Norm Head Motion - ML  5.43 0.35  4.01 0.27  4.13 0.34  4.19 0.39 a, b, c, d
Norm Pelvis Motion - VT  2.87 0.11  2.81 0.10  2.82 0.12  2.91 0.18 ns 
Norm Pelvis Motion - ML  4.44 0.26  3.65 0.22  3.67 0.21  3.69 0.23 ns 
Joint  Kinematics (°)              
Trunk Flexion Angle   13.55 0.81  11.56 0.83  10.77 0.61  11.47 0.72 a 
Trunk Flexion Range   3.18 0.19  3.17 0.17  3.42 0.21  4.02 0.44 ns 
Hip Flx/Ext Range   35.75 0.97  39.64 1.56  41.08 1.03  43.54 1.70 a, c, d 
Knee Flx/Ext Range   47.65 1.13  52.12 1.15  52.52 1.12  53.86 1.41 a, b, c, d
Ankle Dor/Pln Range   23.76 0.71  26.98 0.88  25.53 1.04  25.69 1.12 ns 
Norm Hip Flx/Ext Range   32.73 0.67  32.93 1.00  32.97 0.65  33.46 0.48 ns 
Norm Knee Flx/Ext Range  43.98 1.24  43.64 1.24  42.25 0.99  41.72 0.90 ns 
Norm Ankle Dor/Pln Range  22.02 0.81  22.53 0.75  20.45 0.69  20.09 1.09 a 
ns. No significant differences between the groups (p > 0.05) 
a. PD significantly different to Controls (p < 0.05) 
b. PD Fallers significantly different to PD Non-Fallers (p < 0.05) 
c. PD Fallers significantly different to Control Fallers (p < 0.05) 
d. PD Fallers significantly different to Control Non-Fallers (p < 0.05) 
e. PD Non-Fallers significantly different to Control Fallers (p < 0.05) 
f. PD Non-Fallers significantly different to Control Non-Fallers (p < 0.05) 
g. Control Fallers significantly different to Control Non-Fallers (p < 0.05) 
Table 2. 
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